AbbVie and uMotif support rheumatoid arthritis patients with bring your own device approach to capturing study data

AbbVie has selected the uMotif BYOD (Bring Your Own Device) application to power patient data capture in a new study. The study will investigate the real-world effectiveness of medications used by patients with severe Rheumatoid Arthritis (RA).

The study is taking a “decentralised” approach, combining in-person visits at hospital sites with home-based remote data capture. Patients will be enrolled at multiple hospitals across the UK providing vital face-to-face interaction and active discussions with the study team. Patients will use the uMotif app on their own smart phones, or tablets, to capture and submit their day-to-day symptoms from their location of choice – be that the comfort of their own home or place of work.

Patients will track a range of common RA symptoms using the uMotif app, empowering patients to participate in the research while enabling the study team to capture large volumes of data. This flexible approach will help to enhance data quality and accuracy.

“Collaborating with AbbVie on this decentralised study is incredibly exciting for us,” said Bruce Hellman, Co-Founder of uMotif, “Our mission and core value is to work closely with patients and continually develop well designed patient-centric technology. The app for this particularly study was designed to turbocharge the existing process of capturing high quality data whilst making patients feel comfortable, valued, and actively involved in clinical research”.

Catalysed by the Covid pandemic, uMotif is planning further decentralised trials which put patients at the centre of their trials experience.


About uMotif

uMotif’s mission is to put patients at the centre of clinical research. Designed with patients for patients, the uMotif patient-centric eClinical platform powers site-based to fully decentralised clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture eConsent and large volumes of ePRO, symptom, and wearable device data. Visit